More on telomerase, cancer stem cells and GRN163L-David

"Abstract

Telomerase is an attractive cancer target as it
appears to be required in essentially all tumours for immortalization
of a subset of cells, including cancer stem cells. Moreover,
differences in telomerase expression, telomere length and cell kinetics
between normal and tumour tissues suggest that targeting telomerase
would be relatively safe. Clinical trials are ongoing with a potent and
specific telomerase inhibitor, GRN163L, and with several versions of
telomerase therapeutic vaccines. The prospect of adding
telomerase-based therapies to the growing list of new anticancer
products is promising, but what are the advantages and limitations of
different approaches, and which patients are the most likely to respond?" 

http://www.medscape.com/v...